Find Clinical Trials & Studies

Visit the Research & Education Institute

TER-2013 in Patients with Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

I'm Interested!

Please call
1-866-373-1464

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Solid Tumor

Study Purpose

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

Principal Investigator
Amit Mahipal MD

Department/Division
Cancer (Any Solid Tumor)

UH IRB: STUDY20251443
StudyID: TERM1Y25
ClinicalTrials.gov: NCT07109726

I'm Interested!

Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464